Dr. Luiz R. Goulart , obtained his BSc degrees in Agronomy and Biology (1984), and MSc and PhD degrees at Purdue University in Genetics and Molecular Biology (1987 and 1990), respectively. He was a postdoctoral fellow at the Molecular Pathology Department, Virginia Commonwealth University, in 1999, and at the Department of Medical Microbiology and Immunology, University of California Davis, in 2009-2010, where he was also a visiting professor from 2010 to 2012. Currently, Dr. Goulart is a full professor at the Institute of Genetics and Biochemistry of the Federal University of Uberlandia (since 1989) and adjunct professor at the Department of Medical Microbiology and Immunology of the University of California Davis (since 2013). He is a Distinguished Investigator of the National Research Council of the Brazilian Government (CNPq). His laboratory experience and research emphasis are on molecular biology, immunology, and nanobiotechnology of infectious and chronic-degenerative diseases, with focus on diagnostics and vaccines, including combinatorial technologies, electrochemistry, nanomaterials and biophotonics. He has published 198 peer-review articles, one book and ten book chapters, filed 32 patent applications, supervised 34 postdoctoral fellows, 43 PhD theses, 75 MSc dissertations and 41 undergraduate monographies, and is currently supervising 9 postdoctoral fellows, 18 PhD theses and 2 MSc dissertations. Dr. Goulart is the Coordinator of the Brazilian Nanobiotech Research Network and the National Institute of Science and Technology in Theranostics and Nanobiotechnology, funded by the Brazilian Agencies CAPES, CNPq and FAPEMIG, and one of the pioneers in Brazil in using nanotechnological approaches for human and animal disease diagnostics and vaccines. Dr. Goulart has started up four biotech companies since 1996, and act as consultant on nanobiotechnology and human diseases at CNPq, FAPEMIG and for the Ministry of Health of the Brazilian Government.
Luiz R. Goulart Filho
Laboratory of Nanobiotechnology, Institute of Genetics and Biochemistry, Federal University of Uberlandia (UFU), Campus Umuarama Uberlândia, Minas Gerais
The current frontiers in biological sciences demand an interface among disciplines of biology, chemistry, and physics to achieve new paradigms on applied nanobiotechnologies to health. New rationale is required to use available technologies that intersect among imaging, electrochemistry, biophotonics, nanotechnologies and combinatorial molecules. We will discuss examples of selected epitope-based peptides, combinatorial antibodies, and nucleic acid (aptamers) in association with nanobiotechnologies for multiple applications in biomedical sciences. Combinatorial libraries displaying very diverse set of random peptides, or large repertoire of antibody fragments’ fused to the capsid surface of filamentous phage, or nucleic acid aptamers have been successfully exploited in the discovery of novel biomarkers, and are considered excellent platforms for the discovery of high-affinity ligands. The selected ligands may be directly used in phage-based ELISA immunoassays, flow cytometry, or associated with other infield technologies, resulting in simple, specific, sensitive, and low-cost immunodiagnostic tests. Interestingly, these combinatorial selection platforms have also generated important targets-specific ligands that can be used in joint applications for both diagnostics and therapeutics. It is the only method to obtain specific antibodies bypassing the immunization step, which mimics the maturation process of human antibody in vivo, resulting in high affinity antibody ligands, which may be suitable to human administration and potentially applicable to clinical diagnosis and treatment. Among many applications, biosensing involves the interplay of fundamental disciplines, demanding specific knowledge on physical chemistry (nanoparticles), materials science (polymers), physics (optics and solid state), biology (antigen, antibody, biochemistry, genetics, substrates, and clinical information of diseases) and engineering (electronics and microfabrication). Our aim is to translate these parameters into universal biosensor platforms. Briefly, we will show that combinatorial technologies can reveal functional determinant sites of molecules, which are combined with multiple research tools, techniques, and instruments to enabled entirely novel approaches for diagnostics and therapeutics. The search for universal and robust theranostic platforms have been the highest challenges in the medical field, due to the variable disease spectra, different pathogenetic backgrounds, specific sampling, the complex interactions with vectors and environments, resulting in very diverse phenotypes. Therefore, only multidisciplinary teams and novel nanobiotechnological approaches can meet the demand of smart solutions to control human diseases. Acknowledgments: The authors gratefully acknowledge the financial support of the Brazilian Funding Agencies: CAPES (Rede Nanobiotec/Brasil, Project N. 8), FAPEMIG (Pronex APQ-02413/08), and MCT/CNPq (Institute of Science and Technology in Theranostics and Nanobiotechnology).